Patricia Salvato, MD
Internal Medicine · Houston, TXNPI 1043218845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 849 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 849 payments — averaging $13.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Merck$1K
- Gilead$925
- Viiv Healthcare Company$755
- Johnson & Johnson$737
- Collegium Pharmaceutical, Inc.$552
- plus $6K from 54 others
Across 62 payments — averaging $1438.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Canada Ltd.ltee$29K
- Boehringer Ingelheim$27K
- Hikma Pharmaceuticals USA$23K
- Amgen$5K
- GRT US Holding, Inc.$4K
- Merck$500
What the payments were for
- Food & beverage$11,32599%
- Education$1721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$110
How this compares
$11,497 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 288 | $1,181,829 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 86 | $486,865 |
| Invega HafyeraPaliperidone Palmitate | 23 | $479,778 |
| OzempicSemaglutide | 297 | $358,772 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 81 | $323,005 |
| MounjaroTirzepatide | 259 | $297,010 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 36 | $150,099 |
| IsentressRaltegravir Potassium | 76 | $149,407 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 24 | $123,169 |
| IngrezzaValbenazine Tosylate | 14 | $113,807 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,594 | $111,412 |
| DescovyEmtricitabine/Tenofov Alafenam | 48 | $108,380 |
| LinzessLinaclotide | 120 | $91,736 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 22 | $85,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $83,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $925 | $1,375,785358 claims |
| Janssen Products, LPSymtuza | $100 | $486,86586 claims |
| Novo NordiskOzempic, Rybelsus | $408 | $388,964325 claims |
| Lilly USA, LLCMounjaro | $267 | $297,010259 claims |
| Johnson & JohnsonComplera, Prezcobix, Xarelto | $737 | $224,89591 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay | $755 | $212,07560 claims |
| MerckIsentress | $1,191 | $149,40776 claims |
| AbbVieLinzess, Ubrelvy, Savella | $1,463 | $135,033158 claims |
| PfizerEliquis, Premarin | $402 | $86,175141 claims |
| GSKTrelegy Ellipta | $182 | $83,05894 claims |
| Astellas Pharma US IncMyrbetriq | $231 | $77,918128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $235 | $54,72291 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.